TWI337863B - Use of resveratrol for preparation of a medicament useful for the treatment of influenza virus infections - Google Patents

Use of resveratrol for preparation of a medicament useful for the treatment of influenza virus infections Download PDF

Info

Publication number
TWI337863B
TWI337863B TW092129780A TW92129780A TWI337863B TW I337863 B TWI337863 B TW I337863B TW 092129780 A TW092129780 A TW 092129780A TW 92129780 A TW92129780 A TW 92129780A TW I337863 B TWI337863 B TW I337863B
Authority
TW
Taiwan
Prior art keywords
resveratrol
virus
cells
infection
influenza virus
Prior art date
Application number
TW092129780A
Other languages
English (en)
Chinese (zh)
Other versions
TW200501935A (en
Inventor
Enrico Garaci
Anna Teresa Palamara
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of TW200501935A publication Critical patent/TW200501935A/zh
Application granted granted Critical
Publication of TWI337863B publication Critical patent/TWI337863B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW092129780A 2002-11-06 2003-10-27 Use of resveratrol for preparation of a medicament useful for the treatment of influenza virus infections TWI337863B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000562A ITRM20020562A1 (it) 2002-11-06 2002-11-06 Uso del resveratrolo per la preparazione di un medicamento utile per il trattamento delle infezioni da virus dell'influenza.

Publications (2)

Publication Number Publication Date
TW200501935A TW200501935A (en) 2005-01-16
TWI337863B true TWI337863B (en) 2011-03-01

Family

ID=32310188

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092129780A TWI337863B (en) 2002-11-06 2003-10-27 Use of resveratrol for preparation of a medicament useful for the treatment of influenza virus infections

Country Status (18)

Country Link
US (1) US8431617B2 (enExample)
EP (1) EP1567137B1 (enExample)
JP (1) JP4589118B2 (enExample)
KR (1) KR101060331B1 (enExample)
AR (1) AR041891A1 (enExample)
AT (1) ATE381929T1 (enExample)
AU (1) AU2003279551A1 (enExample)
CA (1) CA2504872C (enExample)
CY (1) CY1107302T1 (enExample)
DE (1) DE60318327T2 (enExample)
DK (1) DK1567137T3 (enExample)
ES (1) ES2295660T3 (enExample)
IT (1) ITRM20020562A1 (enExample)
MX (1) MXPA05004628A (enExample)
PL (1) PL217628B1 (enExample)
PT (1) PT1567137E (enExample)
TW (1) TWI337863B (enExample)
WO (1) WO2004041260A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2626056A1 (en) * 2005-11-18 2007-05-24 Ares Trading S.A. Interferon in influenza
US8629283B2 (en) * 2008-03-06 2014-01-14 Icahn School Of Medicine At Mount Sinai Compounds that modulate negative-sense, single-stranded RNA virus replication and uses thereof
AU2009313657A1 (en) * 2008-11-04 2010-05-14 Metaproteomics, Llc Phytochemical compositions and methods for activating AMP-kinase
WO2010123527A2 (en) * 2008-12-19 2010-10-28 The Regents Of The University Of California Use of epidermal growth factor inhibitors in the treatment of viral infection
KR100950445B1 (ko) 2009-10-26 2010-04-02 주식회사 중앙백신연구소 감초로부터 얻은 조류, 돼지 인플루엔자 및 신종플루에 대한 항바이러스제
US9096585B2 (en) 2010-05-28 2015-08-04 Icahn School Of Medicine At Mount Sinai Antiviral compounds and uses thereof
US9453017B2 (en) * 2011-09-30 2016-09-27 Vanderbilt University Antiviral therapies with phospholipase D inhibitors
PT2952209T (pt) 2014-06-04 2018-05-09 Alfasigma Spa Formulações homogéneas compreendendo ácidos gordos poliinsaturados ómega-3 (n-3 pufa) e resveratrol para administração oral
SI2952180T1 (sl) 2014-06-04 2017-05-31 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Trdne formulacije, ki vsebujejo resveratrol in polinenasičene maščobne kisline omega-3 (n-3 PUFA)
EP3120842A1 (en) * 2015-07-20 2017-01-25 Opterion Health AG Peritoneal therapeutic fluid
KR20170039456A (ko) 2015-10-01 2017-04-11 동아대학교 산학협력단 오동나무로부터 추출한 ｃ-제라닐플라보노이드계 물질을 포함하는 인플루엔자 예방 및 치료용 약학 조성물
JP2018024592A (ja) * 2016-08-09 2018-02-15 株式会社ブレインヘルス 抗生物質含有組成物
CN108893558B (zh) * 2018-05-24 2022-04-05 江苏海宏制药有限公司 一种桑木液原液抗病毒实验方法以及装置
EP4132277B1 (en) * 2020-04-05 2025-11-26 Mong, Michael Systems and methods for treating coronavirus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2778337B1 (fr) * 1998-05-05 2001-08-31 Inst Nat Sante Rech Med Antagonistes des ligands du recepteur des arylhydrocarbures
PE20010540A1 (es) 1999-07-30 2001-05-15 Procter & Gamble Composicion de fitoalexinas estilbenicas util para la profilaxis y tratamiento de sintomas asociados con el resfriado y enfermedades similares a la influenza
DE60015568D1 (de) * 1999-08-13 2004-12-09 Univ Maryland Biotech Inst Zusammensetzungen zur behandlung von viralen infektionen und verfahren dafür

Also Published As

Publication number Publication date
JP4589118B2 (ja) 2010-12-01
DE60318327T2 (de) 2008-12-18
JP2006507295A (ja) 2006-03-02
AR041891A1 (es) 2005-06-01
PL377557A1 (pl) 2006-02-06
CA2504872A1 (en) 2004-05-21
PT1567137E (pt) 2008-02-19
AU2003279551A1 (en) 2004-06-07
EP1567137B1 (en) 2007-12-26
EP1567137A1 (en) 2005-08-31
PL217628B1 (pl) 2014-08-29
TW200501935A (en) 2005-01-16
DK1567137T3 (da) 2008-04-28
WO2004041260A1 (en) 2004-05-21
ITRM20020562A1 (it) 2004-05-07
US20050239906A1 (en) 2005-10-27
US8431617B2 (en) 2013-04-30
CA2504872C (en) 2011-07-05
DE60318327D1 (de) 2008-02-07
MXPA05004628A (es) 2005-09-08
ATE381929T1 (de) 2008-01-15
ES2295660T3 (es) 2008-04-16
KR101060331B1 (ko) 2011-08-30
CY1107302T1 (el) 2012-11-21
KR20050071627A (ko) 2005-07-07

Similar Documents

Publication Publication Date Title
TWI337863B (en) Use of resveratrol for preparation of a medicament useful for the treatment of influenza virus infections
Khandelwal et al. Emetine inhibits replication of RNA and DNA viruses without generating drug-resistant virus variants
EP2471529A2 (en) Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof
Xu et al. Inhibition of peptide BF-30 on influenza A virus infection in vitro/vivo by causing virion membrane fusion
Qian et al. Antiviral effect of lithium chloride on replication of avian leukosis virus subgroup J in cell culture
Johnston et al. Myxoma virus infection of primary human fibroblasts varies with cellular age and is regulated by host interferon responses
Ahmed et al. Antiviral activity of Ribavirin nano-particles against measles virus
CN116370399A (zh) 用于病毒的防护和/或治疗的膜剂及其应用
US7341988B2 (en) Method of treating influenza with geranyl-geranyl acetone
Saikrupa et al. Rational Use of Methylene Blue in COVID-19 Treatment.
US20230248680A1 (en) Use of rigosertib to treat rna virus infections
CN108014129A (zh) 铁离子在抑制rna病毒中的应用
WO2021229602A1 (en) Use of compounds for treating viral infections
CN114762694A (zh) 寡糖转移酶抑制剂在预防和/或治疗新型冠状病毒感染中的应用
WO2022079496A1 (en) A pharmaceutical composition of nitazoxanide, albendazole and pyrantel and method thereof
CZ308937B6 (cs) Použití hem arginátu pro výrobu léčiva pro léčbu infekce beta koronaviry
US20230084839A1 (en) Active agents against coronavirus infections and diseases caused thereby
CN111214472B (zh) 依诺沙星在制备预防和/或治疗黄病毒感染的药物中的应用
Paliwal et al. A COMPREHENSIVE REVIEW ON COVID-19 WITH THEIR TREATMENT APPROACHES
CN116531509A (zh) 一种基于天然萘醌的药物组合物及应用
CN114712342A (zh) 紫草酸在制备抗流感病毒药物中的应用
CN118078824A (zh) 抗马立克氏病病毒的药物以及ra190或甘草酸及其联合使用在药物制备中的应用
CN115813929A (zh) S63845在制备抗流感病毒感染药物中的应用
Desloovere MK2206 inhibits influenza A (H1N1) pdm2009 virus infection
US20110112195A1 (en) Potent and Selective Inhibition by Aurinticarboxylic Acid

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent